Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENTA is quietly +70% since the post I’m replying to from six months ago.
Moral: A dirt-cheap valuation can be a strong catalyst in its own right.
Please elaborate. TIA
The XLO deal is tantamount to a call option for GILD.
XLO—(+130%)—inks GILD collaboration—$43.5M up-front cash (including a $13.5M equity purchase):
https://www.businesswire.com/news/home/20240328734624/en
“poorgradstudent” is on Twitter under his real name, but he hardly ever tweets:
https://twitter.com/Ogut_Ozgur
Indeed he did: #msg-111031090.
FDA—(belatedly)—approves AKBA’s Vafseo—(vadadustat)—for_dialysis_patients—stock declines:
https://finance.yahoo.com/news/akebia-receives-fda-approval-vafseo-002600187.html
He’s a serial dealmaker. Patrick somehow managed to avoid being tarnished by his close association with Martin Shkreli.
BOLD IPOs 7.19M* shares @$16.00:
https://www.businesswire.com/news/home/20240327704934/en
That's a handy chart. I would submit, however, that bioavailability is more relevant than the chart might lead one to believe insofar as it directly or indirectly causes several of the other cited advantages and disadvantages.
Please see #msg-174128961.
VTRS Investor Day slide deck shows 2026 as “anticipated launch date” for Botox-biosimilar collaboration with RVNC:
https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f (slide #14)
If this pans out it will generate material cash flow for RVNC in the next couple of years. The collaboration has $70M of remaining clinical and regulatory milestone payments. The collaboration also has up to $225M of sales-based milestones, although these presumably won’t be triggered until later in the decade.
IBIO—A second company issued a PR today mentioning both AI and obesity drugs—and it was good for a +192% move:
https://finance.yahoo.com/news/ibio-astralbio-announce-transformative-ai-110000784.html
Caveat emptor, LOL.
Loosely similar PR from 2020: #msg-155310524.
The impetus for the VTRS-RVNC Botox-biosimilar program is that the manufacturing of Daxxify generates a complexed 750-kD Botox-biosimilar compound as an intermediate step.
AVTX is +250% in AH trading. The outgoing CEO of AlmataBio (the private company AVTX is acquiring) is Patrick Crutcher, who used to be a co-moderator of this message board.
This deal is structured as a regular-way merger, but it’s conceptually a reverse-merger insofar as AVTX’s lead asset is the one they just licked up from AlmataBio.
The VTRS-RVNC collaboration is for a Botox biosimilar to be approved via the 351(k) FDA pathway—see #msg-155961720. RVNC is responsible for manufacturing and VTRS is responsible for commercialization in all countries except Japan, where RVNC maintains the full rights.
Note: VTRS is the successor company to Mylan.
For CLF the main source of incremental business cited in the WSJ article consists of transformers and related hardware to upgrade the US electrical grid.
What is BLUE’s guidance with respect to attaining profitability?
PIRS terminates all R&D—becomes royalty-collection vehicle:
https://finance.yahoo.com/news/pieris-pharmaceuticals-announces-strategy-maximize-120000564.html
Recent Biotech Bankruptcies/Liquidations/Dissolutions
[Added AMPE, BTTX, GMDA, and NBSE.]
*Emerged from bankruptcy as FCSC.
iHub
Company Date Reference
ADLS 5/11 #msg-62813901
AFFY 6/14 #msg-103663749
AGIX 1/09 #msg-35019458
AKAO 4/19 #msg-148227772
ALNA 9/22 #msg-169875553
ALPIX.PA 11/23 #msg-173275218
ALTU 11/09 #msg-43509933
AMB.TO 8/09 #msg-40145970
AMPE 4/24 #msg-174111257
ANSV 1/10 #msg-45161615
ARAV 1/24 #msg-173646720
ARDM 2/19 #msg-146903332
ARLZ 8/18 #msg-142824112
ARNI 12/17 #msg-137120846
ARTE 12/08 #msg-33895436
ASP.TO 1/23 #msg-171046860
ATHX 1/24 #msg-173589749
ATNX 5/23 #msg-171913749
AXLA 12/23 #msg-173374718
BAXS 11/14 #msg-108147336
BCART.BR 9/23 #msg-172903024
BIND 5/16 #msg-122328088
BIOA 5/18 #msg-140549553
Biolex 7/12 #msg-77324773
BPUR 7/09 #msg-39629524
BTTX 3/24 #msg-174037486
BVTI‡ 3/13 #msg-85440257
CALA 1/23 #msg-170898055
CBIO 6/22 #msg-169273606
CDAK 3/23 #msg-171544942
CJB.TO 7/10 #msg-52557510
CHKT 12/08 #msg-33949508
CLSC 8/09 #msg-40685152
CLVS 12/22 #msg-170599077
CRXT 9/22 #msg-170229149
CWBR 11/23 #msg-173138450
DCGN 11/09 #msg-43629379
DDXS 6/16 #msg-123229557
DMK 2/24 #msg-173773814
DNDN 11/14 #msg-108004147
DXTR 12/17 #msg-136829445
Egenix 1/15 #msg-109921347
ENDP 8/22 #msg-169707980
Epix† 7/09 #msg-39900524
EPRS 7/16 #msg-123687350
EYES 6/20 #msg-156388471
FRTX 9/23 #msg-172854853
GMDA 3/24 #msg-174125313
GNCA 5/22 #msg-168957883
GNTA 8/12 #msg-78123007
GTOP 9/08 #msg-32249160
HEMA 4/12 #msg-74167597
HGEN 7/23 #msg-172432338
HSTO 9/23 #msg-172847239
ILIU 7/17 #msg-133264435
IMMG 8/17 #msg-134305213
IMNP 2/19 #msg-146936897
IMV 5/23 #msg-171814610
INFI 10/23 #msg-172941539
Inspiration 10/12 #msg-81024196
INSY 6/19 #msg-149302493
Introgen†† 12/08 #msg-33947783
Isolagen* 6/09 #msg-38746197
KBIO 12/15 #msg-119489701
KLDO 4/22 #msg-168491485
KV.A 8/12 #msg-78203130
LBPS 6/22 #msg-169255625
LHDX 2/22 #msg-171275021
LIAN 2/24 #msg-173835088
LMDX 12/23 #msg-173530663
MACK 2/24 #msg-173845049
MBRK 4/10 #msg-49658072
MBVX 3/19 #msg-151985211
MIIS 11/08 #msg-33720220
MIPI 12/10 #msg-57646943
MLNT 12/19 #msg-153074747
MNK 10/20 #msg-158843178
MRV.TO 3/23 PR link
NBSE 3/24 #msg-174119874
NEXI 11/23 #msg-173152495
NMTI 4/11 #msg-62251315
NMTR 7/23 SEC link
NOVN 7/23 #msg-172361873
NRGX 3/12 #msg-73415156
NRX 5/16 #msg-122331475
NSTG 2/24 #msg-173773766
NVDL 2/17 #msg-128923029
NVIV 2/24 #msg-173755991
NVLN 1/20 #msg-153111867
NVTA 2/24 #msg-173844970
OBSN.SW 2/24 #msg-173937364
ODT 3/21 #msg-162706983
ONCR 6/23 #msg-172037432
ONCS 6/23 #msg-172145325
OREX 3/18 #msg-139213097
ORPH 3/22 #msg-168169591
OSCI 7/09 #msg-39511719
OTIC 12/22 #msg-170737355
PEAR 4/23 #msg-171639648
PHAS 10/22 #msg-170272758
PLXP 4/23 #msg-171677346
PROMO.ST 10/23 #msg-173007859
PTX 2/19 #msg-146937356
PYMX 4/13 #msg-86313192
PZRX 12/17 #msg-136794351
QTNT 12/22 #msg-170676963
RCPI 8/16 #msg-127560117
REX 11/08 #msg-32189097
ROKA 8/17 #msg-133945967
ROSG 6/18 #msg-141797330
RUBY 2/22 #msg-171270235
RVALL 1/20 #msg-153358221
RVLP 10/23 #msg-173007859
RXPC 7/14 #msg-104103329
SCLX 2/23 #msg-171193757
SGYP 12/18 #msg-145394802
SIEN 2/24 #msg-173834941
SIGA 9/14 #msg-106313111
SIOX 12/22 #msg-170699458
SNNA 9/19 #msg-151196707
SPHS 5/20 #msg-155712447
SRGA 6/23 #msg-172201878
SRNE 2/23 #msg-171193757
SVNT 10/13 #msg-92997648
TDLP 6/11 #msg-64744114
TLCV 12/09 #msg-44751578
TMBR 11/23 #msg-173254229
TOMDF 12/23 #msg-173490278
TPPH 2/08 #msg-26765260
VION 12/09 #msg-44654555
VLRX 2/20 #msg-153741993
VRA 10/07 #msg-18053275
VRAY 7/23 #msg-172361873
VVUS 7/20 #msg-156752080
ZSAN 6/22 #msg-169035970
GMDA—(-82%)—announces “packaged bankruptcy” recapitalization:
https://finance.yahoo.com/news/gamida-cell-announces-commencement-restructuring-110000176.html
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:
https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:
https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html
VTRS Investor Day slide deck shows 2026 as “anticipated launch date” for Botox-biosimilar collaboration with RVNC:
https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f (slide #14)
If this pans out it will generate material cash flow for RVNC in the next couple of years. The collaboration has $70M of remaining clinical and regulatory milestone payments. The collaboration also has up to $225M of sales-based milestones, although these presumably won’t be triggered until later in the decade.
HOTH cites AI and obesity drugs_in_same_PR and gets only a 3% bump, LOL:
(Skeptical) WSJ piece_cites CLF as_major beneficiary of EV transition:
https://www.wsj.com/articles/can-we-power-the-epas-ev-fantasy-electrical-grid-energy-vehicles-a786d535
(Skeptical) WSJ piece_cites CLF as_major beneficiary of EV transition:
https://www.wsj.com/articles/can-we-power-the-epas-ev-fantasy-electrical-grid-energy-vehicles-a786d535
FDA approves MRK’s Winrevair—(sotatercept)—for PAH:
https://www.businesswire.com/news/home/20240326077272/en
This is the first approved drug for PAH that is thought to be disease modifying. MRK acquired sotatercept in the $11.5B buyout of XRLN in 2021 (#msg-166156870).
Thanks. See #msg-174114321 for more color on the same topic.
NBSE prepares for dissolution:
https://www.sec.gov/Archives/edgar/data/1173281/000110465924038432/tm249597-1_pre14a.htm
BLUE—(-13%)—discloses accounting screw-up—issues 2024 patient-start guidance:
https://finance.yahoo.com/news/bluebird-bio-reports-fourth-quarter-110100135.html
FIXX—>QTTB, pursuant to previously announced reverse-merger:
https://www.prnewswire.com/news-releases/q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-private-placement-of-42-million-302098557.html
MRNA’s next-gen COVID vaccine produces_stronger immune response_than Spikevax:
https://www.accesswire.com/846784/moderna-achieves-positive-interim-results-from-phase-3-trial-of-next-generation-covid-19-vaccine
The next-gen vaccine, mRNA-1283, also has a longer shelf life and less onerous storage requirements compared to Spikevax.
MRNA’s next-gen COVID vaccine produces_stronger immune response_than Spikevax:
https://www.accesswire.com/846784/moderna-achieves-positive-interim-results-from-phase-3-trial-of-next-generation-covid-19-vaccine
The next-gen vaccine, mRNA-1283, also has a longer shelf life and less onerous storage requirements compared to Spikevax.